FDA 483 OBSERVATION · #107 OF 1,945 MOST-CITED

Establish, maintain and follow manufacturing SOPs

FDA cited this observation 284 times across 240 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Biologics284
BY FISCAL YEAR
FY202632
FY202535
FY202422
FY202310
FY202222
FY20217
FY20209
FY201932
FY201828
FY201748
FY201639

What this observation means, and how to comply

SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.

21 CFR 111.100

A dietary-supplement manufacturer did not establish, maintain, and follow the written procedures required for its manufacturing operations, so the production and process controls were not defined and consistently applied.

Why FDA writes it — Written procedures are the backbone of dietary-supplement CGMP — the rule explicitly requires them for the manufacturing operations. Without established and followed SOPs, production is uncontrolled and cannot be shown to be consistent.

HOW TO COMPLY
  • Establish and follow written procedures for the manufacturing operations required by 21 CFR 111 subpart E.
  • Cover the batch production record, in-process controls, and the steps needed to ensure specifications are met.
  • Train personnel to the procedures and document the training.
  • Keep procedures current through change control and follow them in practice.
WHY FIRMS GET CITED
  • Required manufacturing SOPs never established, so operations run on undocumented practice.
  • SOPs exist but are not followed, so practice and procedure diverge.
PROFESSIONAL · REMEDIATION PLAYBOOK · SPEQ SYNTHESIS

How to close this finding — and stop it recurring

CHECKING ACCESS

Checking your access…

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 0.1× the rate of the average FDA-cited firm (0.4% vs 7.8%), across 240 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your access…

How FDA worded it — real examples

Written standard operating procedures including all steps to be followed in the processing, storage and distribution of blood and blood components for allogeneic transfusion were not always established, maintained and followed.

Munson Medical Center · Traverse City, Michigan · Biologics · 2026-08-07

Written standard operating procedures including all steps to be followed in the collection of blood and blood components for further manufacturing purposes were not always followed.

HCSC-Blood Center · Bethlehem, Pennsylvania · Biologics · 2026-07-20

Written standard operating procedures including all steps to be followed in the collection of blood and blood components for allogeneic transfusion were not always followed.

New York Blood Center, Inc. · New York, New York · Biologics · 2026-07-17

Written standard operating procedures including all steps to be followed in the collection of blood and blood components for allogeneic transfusion were not always established, maintained and followed.

UC Health Poudre Valley Hospital · Fort Collins, Colorado · Biologics · 2026-07-16

Written standard operating procedures including all steps to be followed in the collection of blood and blood components for allogeneic transfusion and further manufacturing purposes were not always followed.

Sullivan Memorial Blood Center · Fort Benning, Georgia · Biologics · 2026-07-14

Written standard operating procedures including all steps to be followed in the collection, processing, compatibility testing, storage and distribution of blood and blood components for further manufacturing purposes were not always maintained.

New York Blood Center, Inc. · Fishkill, New York · Biologics · 2026-06-23

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Biologics industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →